摘要
Abstract
Anticoagulants are recommended for the prevention and treatment of a wide variety of thrombo-embolic events. Although existing anticoagulants are effective, their usage is limited by parenteral administration or the requirement for frequent monitoring and subsequent dose adjustment. Therefore, there is an urgent need for novel, oral agents with a predictable anticoagulant action. Because of its key position in the coagulation cascade and its limited roles outside of coagulation, Factor Xa has presented as an attractive target for novel anticoagulants. As a result, the past decade has witnessed an explosion of research into small-molecule, oral, direct Factor Xa inhibitors, and some are now in clinical development. Rivaroxaban is currently furthest ahead in its developmental program, having entered phase Ⅲ in 3 indications. It is hoped that, before long, these anticoagulants will allow us to enter an era of convenient, oral anticoagulation, without the need for regular monitoring or dose adjustment.关键词
抗凝药/Xa因子抑制剂/利伐沙班/静脉血栓/急性冠脉综合征/房颤Key words
anticoagulant/ Factor Xa inhibitor/ Rivaroxaban/ vein thrombosis/ acute coronary syndrome/ atrial fibrillation分类
医药卫生
